Stand UP to Rheumatoid Arthritis (SUPRA)

• Status: Not yet recruiting
• Trial end date: 2024-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Marie Hudson, MD
• Collaborators: Lady Davis Institute; McGill University Health Centre/Research Institute of the McGill University Health Centre; Montreal General Hospital
• Treatments: Adalimumab; Etanercept; Golimumab; Tofacitinib; Upadacitinib

Criteria

Inclusion Criteria:

• Age ≥ 18 years;

• Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA;

• Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2).

Exclusion Criteria:

• Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2;

• Contraindication to b/tsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation;

• Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis;

• Unable to provide consent or complete forms (alone or with assistance) in English or French